Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Account Payables
Amounts the company owes suppliers for goods and services received.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 445.2% from a year ago
Account payables stood at $4.51M at the end of Q1 FY2026, up 445.2% from a year earlier.
Context
- Account payables amounted to 42.9% of total assets at the end of Q1 FY2026, up 12.9 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +445.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.18M | +3219.6% |
| FY2023 | 2023-12-31 | 35.47K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Account Payables vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +445.2% is the highest of 9, against a peer median of +55.1%.
- Account payables amounts to 42.9% of total assets for GLSI, versus a peer median of 8.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $71.08M USD | +10.7% | +26.6% | 38.1% | |
| Mar 2026 | $4.73M USD | -17.6% | +236.3% | 4.9% | |
| Mar 2026 | $4.51M USD | +445.2% | — | 42.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.42M USD | +82.0% | +45.5% | 6.6% |
| Mar 2026 | $3.95M USD | +28.2% | +25.3% | 13.3% | |
| Mar 2026 | $3.85M USD | +111.4% | -29.7% | 10.7% | |
| Mar 2026 | CA$2.68M CAD | +244.2% | +28.8% | 32.9% | |
| Mar 2026 | $2.5M USD | -43.9% | +38.7% | 0.9% | |
| Mar 2026 | $889K USD | +194.4% | +3.4% | 0.7% | |
| Peer median (excluding GLSI) | — | +55.1% | +27.7% | 8.6% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.